News about Clinical Trials

Qiagen and APAGE Set Regional Consensus on Rapid Molecular Testing for Gastrointestinal Infections

Qiagen and APAGE Set Regional Consensus on Rapid Molecular Testing for Gastrointestinal Infections

The two-day meeting, held on 20–21 September in collaboration with the Asia-Pacific Association of Gastroenterology (APAGE), convened key opinion leaders from Singapore, Malaysia, Thailand, Indonesia, the Philippines and Australia.

Clinical Trials | 23/09/2025 | By Darshana 119

China's Leads Biolabs Wins FDA Nod to Begin First-in-Human Trial of Novel Autoimmune Therapy

China's Leads Biolabs Wins FDA Nod to Begin First-in-Human Trial of Novel Autoimmune Therapy

The US Food and Drug Administration (FDA) has approved Leads Biolabs’ first-in-human Investigational New Drug (IND) application for LBL-047, a novel therapeutic candidate for the treatment of autoimmune diseases such as systemic lupus erythematosus, dermatomyositis, IgA nephropathy and Sjögren's syndrome.

Clinical Trials | 22/09/2025 | By Dineshwori 231

Wegovy from Novo Nordisk Reduces Risk of Heart Attack, Stroke or Death by 57 Percent Compared to Tirzepatide

Wegovy from Novo Nordisk Reduces Risk of Heart Attack, Stroke or Death by 57 Percent Compared to Tirzepatide

Wegovy (Semaglutide 2.4 mg) reduced risk of heart attack, stroke, or death by 57 percent when compared to Tirzepatide, and 29 percent across all patients, showing heart-protective benefits unique to the Semaglutide molecule.

Clinical Trials | 19/09/2025 | By Dineshwori 128

Aurobindo's Subsidiary CuraTeQ Biologics Completes Phase 3 Clinical Study for Denosumab Biosimilar

Aurobindo's Subsidiary CuraTeQ Biologics Completes Phase 3 Clinical Study for Denosumab Biosimilar

CuraTeQ Biologics, a wholly owned subsidiary of Aurobindo Pharma, has successfully completed a pivotal clinical study of its denosumab biosimilar, evaluated against Amgen’s Prolia in 446 women with postmenopausal osteoporosis.

Clinical Trials | 19/09/2025 | By Dineshwori 232

Greenwich LifeSciences Expands Flamingo-01 Breast Cancer Trial to Ireland

Greenwich LifeSciences Expands Flamingo-01 Breast Cancer Trial to Ireland

Greenwich LifeSciences has expanded its Phase III clinical trial, FLAMINGO-01, evaluating GLSI-100, an immunotherapy aimed at preventing breast cancer recurrences, to Ireland.

Clinical Trials | 18/09/2025 | By Dineshwori 100

Wegovy Cuts Food Noise, Cagrilintide Delivers Significant Weight Loss: Novo Nordisk Unveils New Data at EASD 2025

Wegovy Cuts Food Noise, Cagrilintide Delivers Significant Weight Loss: Novo Nordisk Unveils New Data at EASD 2025

Novo Nordisk presented new findings from its Wegovy and Cagrilintide trials in obesity management at the ongoing European Association for the Study of Diabetes (EASD) 2025 congress in Vienna, Austria.

Clinical Trials | 17/09/2025 | By Dineshwori 227

Gyala Therapeutics Unveils CD84 CAR-T with Strong Pre-clinical Results in Tough Leukemias

Gyala Therapeutics Unveils CD84 CAR-T with Strong Pre-clinical Results in Tough Leukemias

Gyala secures €3 million financing from Invivo Partners, Nara Capital and CDTI Innvierte to launch a Phase I trial in AML patients in H2 2025

Clinical Trials | 17/09/2025 | By Dineshwori

BioAge Labs Initiates Phase 1 Trial of Novel NLRP3 Inhibitor BGE-102 for Obesity Treatment

BioAge Labs Initiates Phase 1 Trial of Novel NLRP3 Inhibitor BGE-102 for Obesity Treatment

BioAge Labs, a clinical-stage biotechnology company based in Emeryville, California, has announced the initiation of a Phase 1 clinical study of BGE-102, an orally available, brain-penetrant small molecule NLRP3 inhibitor being developed for the treatment of obesity.

Clinical Trials | 16/09/2025 | By Dineshwori 116

Akeso Doses First Patient in Global Trial of Cadonilimab for PD-1 Resistant Liver Cancer

Akeso Doses First Patient in Global Trial of Cadonilimab for PD-1 Resistant Liver Cancer

COMPASSION-36, the first global Phase III trial of Cadonilimab, is underway in China, the US, and Europe. It marks a key step in Akeso's effort to advance cancer immunotherapy beyond single-target treatments.

Clinical Trials | 15/09/2025 | By Dineshwori 155

Phrontline Biopharma Announces First Patient Dosed in Phase-I Clinical Trial of TJ101

Phrontline Biopharma Announces First Patient Dosed in Phase-I Clinical Trial of TJ101

The Phase 1 study of TJ101 will assess its safety, tolerability, pharmacokinetics, and early anti-tumor activity in various solid tumors, using a dose escalation and expansion cohort design.

Clinical Trials | 15/09/2025 | By Dineshwori

 
 

 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members